Eosinophilic GI disorder (EGID) biologic selection
Biologic and targeted therapy options for eosinophilic esophagitis (EoE) and other eosinophilic GI disorders (EoGE, EoG, EoC), with mechanism, dose, and positioning.
Evidence tier: Guideline-derived.
| Agent (target) | Indication & evidence level | Dose & key notes |
|---|---|---|
| Dupilumab (anti–IL-4Rα), FDA-approved for EoE | EoE: FDA-approved from age 1 y (≥15 kg), the indication was expanded to ages 1-11 in Jan 2024, so use in that group is on-label. RCT: 59% histologic remission (peak eos <6/hpf) vs 6% placebo (weekly arm). | WEIGHT-BASED, and the EoE schedule differs from the atopic-dermatitis/asthma schedule: 15 to <30 kg → 200 mg SC q2w; 30 to <40 kg → 300 mg SC q2w; ≥40 kg (most adolescents and all adults) → 300 mg SC WEEKLY. No loading dose. Histologic remission in ~60% at 24 weeks; also improves dysphagia and esophageal remodeling. The only FDA-approved biologic for EoE, first-line when dietary elimination fails or is not feasible. |
| Mepolizumab (anti–IL-5), off-label for EoE | EoE: Off-label. Phase 2 RCTs showed significant tissue eosinophil reduction but inconsistent symptom improvement. NOT FDA-approved for EoE. | Phase 2 doses: 750 mg IV q4w or 300 mg SC q4w. Evidence of histologic efficacy without proportional symptom response, insufficient efficacy/symptom correlation to recommend as first-line. May have a role in refractory EoE when dupilumab is unavailable. |
| Benralizumab (anti–IL-5Rα), off-label / phase 2 for EoE | EoE: Phase 2 trials ongoing. Near-complete eosinophil depletion in tissue but early trials did not show significant symptom improvement. NOT FDA-approved for EoE. | 30 mg SC q4w × 3, then q8w. Tissue eosinophil depletion without consistent symptom benefit, not recommended outside clinical trials for EoE. |
| Cendakimab (anti–IL-13), investigational for EoE / EoG | EoE and EoG: phase 3 in EoE; phase 2 in EoG. Histologic and symptomatic responses reported in EoE phase 2. Earlier development codes RPC4046, then CC-93538. | Phase 3 dose: 360 mg SC weekly. It is an IgG1 monoclonal antibody, so it is injected, not oral. Not yet FDA-approved. |
| Lirentelimab (anti–Siglec-8), program did not succeed | Phase 2 ENIGMA was positive on both histologic and symptomatic endpoints, but the confirmatory studies were not: ENIGMA-2 (phase 3, EoG/EoD) and KRYPTOS (phase 2/3, EoE) both met their histologic co-primary endpoint yet MISSED the patient-reported symptom co-primary endpoint (topline Dec 2021). | IV infusion q4w. Depletes eosinophils and inhibits mast cells via Siglec-8. Not approved, and no longer an active near-term prospect, do not counsel patients toward it or defer treatment awaiting it. Retained here because the positive phase 2 is still widely cited. |
| Topical corticosteroids (fluticasone MDI swallowed, budesonide oral susp) | EoE first-line (non-biologic): FDA-approved budesonide oral suspension (Eohilia) and budesonide orodispersible tablet (Jorveza, Europe) for induction in EoE. | Budesonide oral susp (Eohilia): 2 mg/10 mL BID × 12 weeks; maintenance not established. Fluticasone MDI swallowed: 440-880 mcg/d. First-line pharmacotherapy before or alongside dietary elimination; safer long-term profile than systemic steroids for EoE maintenance. |
| Dietary elimination (6-food, 4-food, 2-food, or targeted based on testing) | EoE first-line (non-biologic): Histologic remission in 40-95% depending on elimination strategy; most evidence for 6-food elimination diet. | 6FED (milk, wheat, egg, soy, nuts, seafood): ~72% histologic remission; most burdensome. 4FED (milk, wheat, egg, soy): ~54%. 2FED (milk, wheat): ~43%. Start with 2FED or 4FED for practicality; escalate if insufficient. Requires endoscopy to assess response. |
Notes
- Dupilumab (Dupixent) is the ONLY FDA-approved biologic for EoE. All other biologics in this table are off-label or investigational for EoE/EGID.
- EGID outside the esophagus (eosinophilic gastritis, enteritis, colitis) has no FDA-approved biologic therapy, lirentelimab (anti-Siglec-8) is the most advanced investigational agent.
- Histologic remission threshold for EoE: peak eosinophil count <15/hpf (some guidelines use <6/hpf for deep remission).
- Endoscopy with biopsy is required to assess treatment response, symptomatic improvement alone is insufficient because EoE can be histologically active with few symptoms (fibro-stenotic remodeling continues silently).
- PPI, swallowed topical corticosteroid, dietary elimination, and dupilumab are all first-line options chosen by shared decision-making, a PPI trial is not a mandatory gate before the others (ACG 2025). PPI-responsive esophageal eosinophilia is now recognised as part of the EoE spectrum rather than a separate diagnosis.
Evidence & citations
- Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317-2330. PMID 36546624
- Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111-122. PMID 31593702
- Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology. 2018;155(4):1022-1033. PMID 30009819
- Dellon ES, Muir AB, Katzka DA, et al. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis. Am J Gastroenterol. 2025;120(1):31-59. PMID 39745304
Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.